Synergy of entry inhibitors with direct-acting antivirals uncovers novel combinations for prevention and treatment of hepatitis C

OBJECTIVE: Although direct-acting antiviral agents (DAAs) have markedly improved the outcome of treatment in chronic HCV infection, there continues to be an unmet medical need for improved therapies in difficult-to-treat patients as well as liver graft infection. Viral entry is a promising target fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiao, Fei, Fofana, Isabel, Thumann, Christine, Mailly, Laurent, Alles, Roxane, Robinet, Eric, Meyer, Nicolas, Schaeffer, Mickaël, Habersetzer, François, Doffoël, Michel, Leyssen, Pieter, Neyts, Johan, Zeisel, Mirjam B, Baumert, Thomas F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2015
Materias:
Hepatology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4345833/
https://www.ncbi.nlm.nih.gov/pubmed/24848265
http://dx.doi.org/10.1136/gutjnl-2013-306155

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4345833/
https://www.ncbi.nlm.nih.gov/pubmed/24848265
http://dx.doi.org/10.1136/gutjnl-2013-306155

Ejemplares similares